Atopic dermatitis is also known as atopic eczema, it is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Atopic Dermatitis treatment market is rapidly growing due to factors such as growing prevalence of AD, significant unmet needs, promising pipeline molecules would fuel the market growth of atopic dermatitis treatment.
The report titled Atopic Dermatitis (AD) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall Atopic Dermatitis (AD) treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug type and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AD treatment market. Pipeline analysis of AD treatment molecule and global epidemiology data have been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AD treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global AD treatment market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
Atopic dermatitis (AD) also referred as atopic eczema, is an inflammatory disease of the skin, in which the skin becomes extremely itchy and inflamed, causing redness, swelling, vesicle formation. There is no cure for AD but medications are used to relief itching and prevent new outbreaks. It is studied that, currently anti-inflammatory agents held largest market share in global atopic dermatitis treatment market. Among considered anti-inflammatory segment corticosteroids is major revenue generating segment as these are preferred as first line treatment after failure of skin care and moisturizers due to its effectiveness. It is estimated that new product launch would drive the AD treatment market growth during forecast period. Pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab and tralokinumab are expected to show AD treatment market growth during forecast period. However, adverse effects associated with medication and poor treatment compliance in some countries may negatively impacting AD treatment market growth.
Atopic dermatitis (AD) is a chronic, inflammatory disease of the skin characterized by dry, itchy skin. The prevalence of AD is approximately 15 - 20% in children and 1-3% of adults worldwide and the incidence has increased by 2 to 3 folds during the past decades in industrialized countries. Among the considered geographical segment, North America was major revenue generating segment in the base year 2016. Some factors such as increase in prevalence of AD, higher treatment awareness, swift adoption of novel medications, better reimbursement policies in healthcare systems are the prime contributors of the dominance in North America Atopic dermatitis market. Expenditure on healthcare is highest in the United States as compared to other nations is another factor contributing growth of AD treatment market. According to American Academy of Dermatology approximately 10 to 20 percent of childrens in the United States develop atopic dermatitis; AD affects more than 28 million people of all ages in the United States alone. It is estimated that, Asia Pacific will show highest AD treatment market growth during forecast period due to increasing healthcare awareness among general patient population, developing economic conditions, growing number of investment and partnering of key player with local manufacturers.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Atopic Dermatitis (AD) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall Atopic Dermatitis (AD) treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug type and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AD treatment market. Pipeline analysis of AD treatment molecule and global epidemiology data have been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AD treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global AD treatment market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
Atopic dermatitis (AD) also referred as atopic eczema, is an inflammatory disease of the skin, in which the skin becomes extremely itchy and inflamed, causing redness, swelling, vesicle formation. There is no cure for AD but medications are used to relief itching and prevent new outbreaks. It is studied that, currently anti-inflammatory agents held largest market share in global atopic dermatitis treatment market. Among considered anti-inflammatory segment corticosteroids is major revenue generating segment as these are preferred as first line treatment after failure of skin care and moisturizers due to its effectiveness. It is estimated that new product launch would drive the AD treatment market growth during forecast period. Pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab and tralokinumab are expected to show AD treatment market growth during forecast period. However, adverse effects associated with medication and poor treatment compliance in some countries may negatively impacting AD treatment market growth.
Atopic dermatitis (AD) is a chronic, inflammatory disease of the skin characterized by dry, itchy skin. The prevalence of AD is approximately 15 - 20% in children and 1-3% of adults worldwide and the incidence has increased by 2 to 3 folds during the past decades in industrialized countries. Among the considered geographical segment, North America was major revenue generating segment in the base year 2016. Some factors such as increase in prevalence of AD, higher treatment awareness, swift adoption of novel medications, better reimbursement policies in healthcare systems are the prime contributors of the dominance in North America Atopic dermatitis market. Expenditure on healthcare is highest in the United States as compared to other nations is another factor contributing growth of AD treatment market. According to American Academy of Dermatology approximately 10 to 20 percent of childrens in the United States develop atopic dermatitis; AD affects more than 28 million people of all ages in the United States alone. It is estimated that, Asia Pacific will show highest AD treatment market growth during forecast period due to increasing healthcare awareness among general patient population, developing economic conditions, growing number of investment and partnering of key player with local manufacturers.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Atopic Dermatitis (AD) Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Atopic Dermatitis (AD) Treatment market and their expected impact during the forecast period.
Market Segmentation
Drug
- Anti-inflammatory agents
- Corticosteroids
- Calcineurin Inhibitors
- Antihistamines
- Immunomodulators
- Interleukin Inhibitors
- Topical Phosphodiesterase-4 (PDE-4) Inhibitors
- Antiviral agents
- Antibiotics
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Atopic Dermatitis (AD) Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Atopic Dermatitis (AD) Treatment market?
- Which is the largest regional market for Atopic Dermatitis (AD) Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Atopic Dermatitis (AD) Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Atopic Dermatitis (AD) Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Atopic Dermatitis (AD) Treatment Market: Competitive Analysis
4. Atopic Dermatitis (AD) Treatment Market: Macro Analysis & Market Dynamics
5. Atopic Dermatitis (AD) Treatment Market: By Drug, 2020-2030, USD (Million)
6. North America Atopic Dermatitis (AD) Treatment Market, 2020-2030, USD (Million)
7. UK and European Union Atopic Dermatitis (AD) Treatment Market, 2020-2030, USD (Million)
8. Asia Pacific Atopic Dermatitis (AD) Treatment Market, 2020-2030, USD (Million)
9. Latin America Atopic Dermatitis (AD) Treatment Market, 2020-2030, USD (Million)
10. Middle East and Africa Atopic Dermatitis (AD) Treatment Market, 2020-2030, USD (Million)
11. Company Profile
List of Figures
List of Tables
Companies Mentioned
- AbbieVie Inc.
- Encore Dermatology Inc.
- F. Hoffmann-La Roche AG
- Glaxosmithkline plc.
- LEO Pharma A/S
- Medimmune LLC. (Astrazeneca)
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Valeant Pharmaceuticals Inc.